You have 0 items in your cart
Dapiglutide is one of the more unusual experimental metabolic peptides because it was designed to do more than influence appetite and body weight.
It combines activity at two receptors:
- GLP-1
- GLP-2
GLP-1 is already well known for its role in appetite and glucose regulation.
GLP-2 is very different. It is involved primarily in intestinal growth, gut-barrier integrity and gastrointestinal biology.
The idea behind dapiglutide was therefore unusual:
combine the weight-reducing effects of GLP-1 with potential improvements in intestinal barrier function through GLP-2.
Clinical research has produced interesting results, but there is an important twist: Zealand Pharma has now paused further development of dapiglutide as part of its portfolio strategy. (Zealand Pharma)
What Is Dapiglutide?
Dapiglutide is a long-acting experimental peptide developed by Zealand Pharma.
It is designed as a dual GLP-1 receptor and GLP-2 receptor agonist.
The compound was developed for once-weekly subcutaneous administration.
Its intended advantage was not simply greater weight reduction.
Researchers wanted to investigate whether GLP-2 signalling could address some of the inflammatory and gastrointestinal changes associated with obesity while GLP-1 reduced appetite and food intake. (Zealand Pharma)
What Does GLP-1 Do?
GLP-1 is a naturally occurring peptide hormone released after eating.
It influences:
- appetite
- satiety
- insulin secretion
- glucose regulation
- gastric emptying
Activating GLP-1 receptors can therefore reduce food intake and help regulate blood glucose.
This pathway is already used by several established metabolic medicines.
What Is GLP-2?
GLP-2 is another peptide produced in the intestine.
But its main biological role is very different from GLP-1.
GLP-2 is strongly associated with:
- intestinal growth
- maintenance of the intestinal lining
- nutrient absorption
- intestinal blood flow
- gut-barrier integrity
GLP-2 analogues are already being investigated and used in conditions involving intestinal failure and short bowel syndrome.
Dapiglutide attempted to bring this gut-focused pathway into obesity research.
Why Might Gut-Barrier Function Matter in Obesity?
The gastrointestinal tract contains an enormous population of bacteria.
Under normal conditions, the intestinal barrier helps keep bacteria and bacterial products inside the gut.
Research suggests that obesity can be associated with changes in intestinal permeability and the gut microbiome.
This may allow greater exposure to bacterial products capable of contributing to low-grade systemic inflammation.
Zealand Pharma’s rationale for dapiglutide was that improving intestinal barrier function through GLP-2 might potentially reduce this inflammatory burden. (Zealand Pharma)
What Does “Leaky Gut” Actually Mean?
The phrase “leaky gut” is frequently used online in ways that oversimplify the science.
In research, the relevant concept is increased intestinal permeability.
The cells lining the intestine normally form a controlled barrier.
Changes in the junctions between these cells can potentially increase movement of molecules from the intestinal lumen into surrounding tissue and circulation.
Researchers are investigating whether this contributes to metabolic inflammation.
Dapiglutide was designed partly around this biological hypothesis.
Why Combine GLP-1 and GLP-2?
The combination attempts to target two different components of metabolic disease.
GLP-1:
reduces food intake and supports weight reduction
while GLP-2 may:
support intestinal structure and barrier function.
In theory, this could produce benefits beyond those expected from GLP-1 receptor activation alone.
That theory, however, still requires clinical proof.
What Did the Early Phase 1b Research Show?
Zealand Pharma evaluated higher doses of dapiglutide in a Phase 1b clinical study.
Thirty participants received dapiglutide or placebo for 28 weekly doses.
The participants had a median baseline weight of approximately 91.9 kg and a median BMI of 28.8.
At week 28, Zealand reported an estimated average body-weight reduction of approximately:
11.6% with dapiglutide
compared with:
0.2% with placebo.
No formal diet or exercise programme was included in the study. (Zealand Pharma)
Was Dapiglutide Well Tolerated?
In that Phase 1b study, Zealand reported no severe or serious treatment-emergent adverse events.
The most common adverse effects were gastrointestinal, particularly:
- nausea
- vomiting
Two participants withdrew because of adverse events, including one withdrawal associated with gastrointestinal effects.
Overall, Zealand described the gastrointestinal profile as broadly consistent with other incretin therapies. (Zealand Pharma)
What Did the Independent Phase 2a Trial Show?
A separate investigator-led proof-of-concept study was published in EClinicalMedicine in 2026.
This trial enrolled 54 adults with obesity.
Participants received:
- 4 mg dapiglutide
- 6 mg dapiglutide
- or placebo
once weekly for 12 weeks.
Unlike the longer company-sponsored Phase 1b study, this trial did not demonstrate a statistically significant reduction in body weight versus placebo at 12 weeks. (PubMed)
How Much Weight Was Lost in the Phase 2a Trial?
In the primary analysis, the 6 mg dapiglutide group had an average body-weight change of approximately:
–2.1%
relative to placebo.
The difference did not reach statistical significance.
Researchers also reported that dapiglutide appeared generally safe and well tolerated, with reduced appetite and nausea among the commonly reported adverse events. (PubMed)
Why Were the Two Studies So Different?
There are several possible reasons.
The studies differed in:
- duration
- doses
- participant characteristics
- trial design
- sample size
The Phase 1b programme lasted approximately 28 weeks.
The independent proof-of-concept trial lasted only 12 weeks.
Many metabolic peptides produce increasingly large weight changes over several months, so a shorter study may underestimate the eventual effect.
However, it is equally important not to assume that longer treatment would automatically have produced strong results in the Phase 2a trial.
Was Dapiglutide Moving Toward Phase 2?
Yes.
The programme had been described as Phase 2 ready.
However, Zealand Pharma ultimately decided not to proceed with further investment at that time. (Zealand Pharma)
Why Was Development Paused?
This is one of the most important parts of the dapiglutide story.
Zealand stated that dapiglutide had shown potential for competitive weight reduction and that there remained a strong scientific rationale for GLP-1/GLP-2 dual agonism.
But the company also noted that the GLP-1 field had become increasingly crowded.
Demonstrating that dapiglutide could provide a meaningful advantage through reduced inflammation or improved intestinal-barrier biology would require long and complex clinical trials.
Zealand therefore paused further investment as part of its portfolio management strategy. (Zealand Pharma)
Does a Paused Programme Mean the Drug Failed?
Not necessarily.
Drug-development programmes can stop for many reasons.
These include:
- lack of effectiveness
- safety concerns
- manufacturing problems
- commercial competition
- limited differentiation
- cost
- strategic prioritisation
In dapiglutide’s case, Zealand explicitly described the decision as active portfolio management, rather than announcing a major safety failure. (Zealand Pharma)
The company is investing heavily in other metabolic programmes including petrelintide and survodutide.
Why Is Dapiglutide Still Scientifically Interesting?
The compound tests an unusual hypothesis:
Could treating obesity through both appetite regulation and intestinal-barrier biology provide broader benefits than appetite regulation alone?
That is a scientifically valuable question even if dapiglutide itself never reaches the market.
Negative, mixed or commercially discontinued drug programmes can still teach researchers a great deal about which biological pathways are worth pursuing.
Could GLP-2 Reduce Inflammation?
Potentially, although this is not yet established as a clinical obesity treatment.
GLP-2 has biological effects on intestinal tissue that may improve barrier function.
If better barrier integrity reduces exposure to bacterial components, systemic inflammatory signalling could theoretically fall.
This was part of the rationale behind dapiglutide.
The challenge is proving that this translates into a clinically meaningful benefit beyond ordinary GLP-1 treatment.
That has not yet been demonstrated.
How Is Dapiglutide Different From Tirzepatide?
Tirzepatide targets:
GIP + GLP-1
Dapiglutide targets:
GLP-1 + GLP-2
The second receptor is therefore completely different.
Tirzepatide combines two incretin pathways largely focused on glucose regulation, appetite and metabolism.
Dapiglutide added a pathway strongly associated with intestinal biology.
How Is Dapiglutide Different From Survodutide?
Survodutide targets:
GLP-1 + glucagon
Dapiglutide targets:
GLP-1 + GLP-2
Survodutide therefore adds a pathway associated with energy expenditure and liver metabolism.
Dapiglutide adds a pathway associated with intestinal structure and barrier function.
How Is Dapiglutide Different From Petrelintide?
Petrelintide is an amylin analogue.
Its primary strategy involves:
- satiety
- food intake
- amylin signalling
Dapiglutide is fundamentally different because it combines GLP-1 with intestinal GLP-2 signalling.
Is Dapiglutide a Peptide?
Yes.
Dapiglutide is a long-acting dual GLP-1/GLP-2 receptor agonist peptide.
It therefore represents a genuine example of multi-receptor peptide engineering.
Is Dapiglutide Approved?
No.
Dapiglutide remains investigational.
More importantly, its development programme is currently paused.
Zealand’s latest pipeline lists the compound as:
Phase 2 ready — development paused. (Zealand Pharma)
There is therefore no active late-stage programme demonstrating that it is moving toward regulatory approval.
Could Development Restart?
Possibly.
A paused programme is not necessarily permanently abandoned.
A company could:
- restart development
- license the compound to another organisation
- investigate another indication
- redesign the trial strategy
But there is currently no announcement establishing that dapiglutide development will restart.
Why Is the Story Useful for Understanding Peptide Research?
Dapiglutide highlights something that is often missed when people discuss experimental peptides.
An interesting mechanism and encouraging early results do not guarantee commercial development.
Researchers must also ask:
Does the compound provide enough advantage over existing treatments to justify enormous Phase 2 and Phase 3 development costs?
In a rapidly advancing area such as obesity medicine, that threshold is increasingly high.
The Bottom Line
Dapiglutide is an experimental once-weekly GLP-1/GLP-2 dual receptor agonist designed to combine weight-reducing GLP-1 activity with potential improvements in intestinal-barrier function through GLP-2.
A longer Phase 1b study involving 30 participants reported an estimated average weight reduction of approximately 11.6% after 28 weeks, compared with 0.2% with placebo. (Zealand Pharma)
However, an independent 2026 proof-of-concept trial involving 54 adults found that 12 weeks of dapiglutide did not produce a statistically significant body-weight difference from placebo. (PubMed)
The compound remains scientifically interesting because GLP-1/GLP-2 dual agonism offers a genuinely different approach to metabolic disease.
But Zealand Pharma has currently paused further development, explaining that demonstrating meaningful differentiation through effects on inflammation and intestinal-barrier biology would require substantial additional research. (Zealand Pharma)
That makes dapiglutide an especially useful Research Hub case study.
It shows that emerging peptide research is not simply a race to find the next successful compound.
Sometimes the most valuable scientific question is why an interesting mechanism doesn’t immediately progress, and what researchers learn from it.
This article is for research and educational purposes only. Dapiglutide remains investigational, and its development programme is currently paused.